Clinical trials: Urinary System Tumor
Cancer, Lung Cancer
Immune Related-adverse Events in Patients Receiving Immune Checkpoint Inhibitors
The recent introduction of anti-PD-1 (nivolumab and pembrolizumab) and anti- PD-L1 (atezolizumab, durvalumab, avelumab) immune checkpoint inhibitors revolutionized oncological guidelines.
- Conditions
- Cancer, Lung Cancer, Renal Cell Carcinoma, Melanoma
- Trial name
- ICI-DISCOVER (NCT04268368)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Università Politecnica delle Marche
Bladder Tumor (TURBT), Bladder (Urothelial, Transitional Cell) Cancer
The Effect of Video Calls With Family Members During Operating Room Waiting on Stress, Anxiety, and Surgical Fear in Patients Undergoing Transurethral Resection of Bladder Tumor
This study aims to investigate the effect of video calls with family members during the preoperative waiting period in the operating room on stress, anxiety, and surgical fear in patients undergoing transurethral resection of…
- Trial name
- NCT07203989
- Testing
- family-supported care
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 124 people
- Sponsor
- Bitlis Eren University
Kidney Cancers
Evaluation of 68Ga-PSMA PET-CT in the Initial Staging of Advanced Renal Cell Carcinomas - A Prospective, Multicentre, Open-label Study
Kidney cancer in adults is the seventh leading cause of cancer-related death in France. Early and accurate imaging of the primary tumour and the identification of metastatic sites are major prognostic factors that are crucial for…
- Trial name
- REIN-TEP PSMA (NCT07624578)
- Testing
- 68Ga-PSMA PET-CT scan
- Sponsor
- Assistance Publique Hopitaux De Marseille
Urinary Bladder Neoplasms
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Researchers are looking for new ways to treat muscle-invasive bladder cancer (MIBC). MIBC is a type of cancer that has not spread from the muscles in the bladder to other parts of the body.
- Trial name
- NCT04241185
- Testing
- Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy (Bladder and pelvic nodes)
- Where
- 134 sites in United States, Australia and 23 more
- Volunteers
- 520 people
- Sponsor
- Merck Sharp & Dohme LLC
Renal Cell Cancer
Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Primary Objectives: 1. To compare the overall survival of metastatic renal cell carcinoma (RCC) patients undergoing HLA-matched related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation (NST) using…
- Trial name
- NCT00429026
- Testing
- Fludarabine, Melphalan, Cyclophosphamide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer, Head and Neck Cancer
NGR-TNF in Treating Patients With Advanced Solid Tumors
RATIONALE: Targeted therapy with tumor necrosis factor combined with a fusion protein may stop the growth of solid tumors by stopping blood flow to the tumor.
- Conditions
- Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00098943
- Testing
- CNGRC peptide-TNF alpha conjugate
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 70 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer
This phase I/II trial is studying the side effects and best dose of CCI-779 and bevacizumab and to see how well they work in treating patients with metastatic or unresectable kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00112840
- Testing
- CCI-779, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Advanced Solid Tumor
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in…
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
- Trial name
- PRESERVE-001 (NCT04140526)
- Testing
- ONC-392, Pembrolizumab, Docetaxel
- Where
- 37 sites in United States, Australia
- Volunteers
- 733 people
- Sponsor
- OncoC4, Inc.
Advanced Solid Tumor
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
This is a first-in-human (FIH), open-label, multi-site study which will evaluate the safety, efficacy, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 in participants with advanced solid…
- Trial name
- NCT06750185
- Testing
- BNT317 DL1, BNT317 DL2, BNT317 DL3
- Where
- 11 sites in United States, Australia
- Volunteers
- 248 people
- Sponsor
- BioNTech SE
Kidney Neoplasms
The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy
The objective of this study is to assess whether using a different type of suture (barbed sutures) during partial nephrectomy results in fewer postoperative complications than with traditional sutures (non-barbed).
- Trial name
- NCT01413607
- Testing
- Quill knotless tissue-closure device, 2-0 absorbable vicryl suture
- Where
- Canada
- Volunteers
- 65 people
- Sponsor
- Ricardo Rendon
Locally Advanced or Metastatic Urothelial Carcinoma
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
The purpose of this study is to assess the safety and efficacy of avelumab in combination with other anti-tumor agents as a maintenance treatment in participants with bladder cancer.
- Trial name
- NCT05327530
- Testing
- Avelumab, Sacituzumab Govitecan (SG), M6223
- Where
- 98 sites in United States, Australia and 10 more
- Volunteers
- 256 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Colon Cancer, Lung Cancer
A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors
Background: Fluciclatide is a small cyclic peptide containing the RGD tri-peptide, which preferentially binds with high affinity to alpha(v)beta(3) integrins, which are up-regulated in and may regulate angiogenesis.
- Conditions
- Colon Cancer, Lung Cancer, Cervical Cancer, Renal Cell Carcinoma
- Trial name
- NCT01176500
- Testing
- (18)Fluciclatide
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
Bakircay University Cigli Training and Research Hospital
The aim of the study is to investigate the oncological outcomes of obturator nerve blockade in patients with lateral wall localized non-muscle invasive bladder cancer
- Trial name
- BUCEAH (NCT04683536)
- Testing
- Obturator nerve blockade
- Volunteers
- 106 people
- Sponsor
- Recep Tayyip Erdogan University Training and Research Hospital
Metastatic Renal Cell Carcinoma, Kidney Cancer
Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma
The purpose of PRORECECA is to test whether adding weekly active patient-reported outcomes to the treatment of patients with metastatic renal cell carcinoma can improve patient-reported physical function.
- Conditions
- Metastatic Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasm, Urologic Cancer
- Trial name
- PRORECECA (NCT05135832)
- Testing
- Electronic patient-reported outcomes regarding symptoms and health-related quality of life
- Where
- Denmark
- Volunteers
- 174 people
- Sponsor
- Herlev and Gentofte Hospital
Metastatic Renal Cell Carcinoma, Metastatic Melanoma
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
The purpose of this registry is to collect information on patients who are receiving treatment with Proleukin in an organized way, and to learn more about patient care during and after treatment.
- Trial name
- NCT01415167
- Where
- 45 sites in United States
- Volunteers
- 1,690 people
- Sponsor
- Prometheus Laboratories
Gynecologic Cancer, Skin Cancer
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
This is a randomized open-label multicentre Phase III superiority study of the effect of adding SBRT to the standard of care treatment on overall survival in patients with rare oligometastatic cancers.
- Conditions
- Gynecologic Cancer, Skin Cancer, Head and Neck Cancer, Sarcoma
- Trial name
- OligoRARE (NCT04498767)
- Testing
- Stereotactic body radiotherapy, Palliative RT
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 200 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent Superficial Bladder Cancer, Distilled Water
Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection
The purpose of this study is to compare and evaluate the efficacy of distilled water vs Mitomycin C on preventing the recurrences of intermediate risk group recurrent superficial bladder cancer administered as a single dose…
- Trial name
- NCT00816075
- Testing
- distilled water
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Bozyaka Training and Research Hospital
Breast Cancer, Colorectal Cancer
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Vaccines made from a patient's tumor tissue may make the body build an immune response to kill tumor…
- Conditions
- Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00002475
- Testing
- allogeneic tumor cell vaccine, autologous tumor cell vaccine, recombinant interferon alfa
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- St. Vincent Medical Center - Los Angeles
Bladder Cancer
PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
The primary objective of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of PF-07225570 alone or in combination with an anti-PD-1 antibody in participants with recurrent…
- Trial name
- NCT05259397
- Testing
- PF-07225570, sasanlimab
- Where
- 4 sites in United States, Poland
- Sponsor
- Pfizer
Carcinoma, Renal Cell
Exploring the Influence of Clinical Factors on the Prognosis of Papillary Renal Cell Carcinoma
Patients with renal cell carcinoma who were admitted to the First Affiliated Hospital of Sun Yat-sen University from February 1, 2021, to February 1, 2022, and met the following inclusion and exclusion criteria were collected.
- Trial name
- NCT06111560
- Testing
- We do not have any interventions. This study is based on obseravation.
- Volunteers
- 160 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.